Categories LATEST

No end in sight for Johnson & Johnson’s asbestos woes

There is more trouble for Johnson & Johnson, the embattled baby care products maker facing multiple litigations over sale of hazardous products. The New Jersey-based company this week lost the first trial in a lawsuit related to alleged use of asbestos in its baby care powder, less than a year after being slapped a record $417-million fine in a similar case.

In the latest of a serious of lawsuits filed against the company over the last few years, a state court in New Jersey ruled that J&J’s talc-based baby power contained materials that cause serious health issues like cancer, and ordered the company to pay $37 million to a New Jersey-resident as compensation.

Stephen Lanzo, the complainant, alleged he suffered from mesothelioma, a dangerous form of cancer caused by exposure to asbestos, after using the company’s talc powder products regularly for more than 45 years. While awarding $30 million to Lanzo and $7 million to his wife, the judge held the company and its talc supplier based in France responsible for the plaintiff’s condition.

Meanwhile, J&J dismissed the charges and claimed its baby care products did not contain asbestos and were safe for consumption.

A New Jersey jury ordered J&J to pay $37 million to a man in damages

Since its incorporation more than a century ago, the maker of Band-Aid has faced a number of scandals, product recalls and federal investigations, before getting embroiled in a mesh of talc-related lawsuits over the last decade. Though a South Dakota jury had found the company guilty of negligence in the first trial related to talc in 2013, it did not impose any fine.

What followed was a flood of lawsuits, filed mainly by women who claimed to have developed ovarian cancer after being exposed to the company’s baby powder. As the number of complaints ballooned, jurists combined the pre-trial procedures of several hundreds of lawsuits into a multidistrict litigation for convenience.

As long as the company continues to make profit in billions of dollars, its finances will remain insulated from such setbacks. Unperturbed by the legal entanglements, the company is reportedly developing as many as 11 new pharmaceutical formulations for various diseases and most of them are expected to become ‘megadrugs’ in a few years.

Interestingly, J&J’s stock was impacted only on a few occasions throughout its troubled journey that is marked by fighting cases and paying damages.

But, there is no doubt the world’s largest drugmaker – the lion’s share of J&J’s revenues come from pharmaceutical products and equipment –  has lost its self-proclaimed status of being a ‘people-before-profits’ enterprise.

Among its peers, the firm that comes closest to J&J in the scale of litigations is Merck & Co. (MRK), which coughed up nearly $5 billion by 2007 for settling 27,000 lawsuits involving people affected by its Vioxx painkiller.

Most Popular

AVGO Earnings: All you need to know about Broadcom Q1 2021 earnings results

Broadcom Limited (NASDAQ: AVGO) reported first quarter 2021 earnings results today. Total revenue increased 14% year-over-year to $6.65 billion. GAAP net income was $1.3 billion, or $3.05 per share, compared

Infographic: Costco (COST) Q2 2021 sales up 15%; earnings miss

Retail giant Costco Wholesale Corporation (NASDAQ: COST) reported higher earnings and revenues for the second quarter of 2021. Earnings missed analysts’ expectations, while sales beat. Net profit was $951 million

Will shifting to as-a-service model help Hewlett Packard in emerging stronger from COVID?

With the corporate world rapidly shifting to cloud-native computing after the virus outbreak changed work culture and the way businesses operate, technology providers are aggressively innovating their offerings. Hewlett Packard

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top